Преодолеть предположение: эффективность терапии, корректирующей болезни, и степень рецидива при повторном выбросе множественных склерозов.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rodriguez de Antonio Luis A, García-Castañón Inmaculada, González-Suárez Inés, Oreja-Guevara Celia
Аннотация
Оригинал публикации
Breaking the assumption: Disease-modifying therapy efficacy and relapse severity in relapsing-remitting multiple sclerosis.
BACKGROUND: The severity of relapses is lower in patients treated with DMTs compared to untreated patients. Although Disease-modifying treatments (DMTs) differ considerably in their efficacy for relapse prevention, the specific impact of different DMTs on relapse severity has not yet been thoroughly investigated.
OBJECTIVE: To study the relationship between DMT use, relapse severity and recovery outcomes in relapsing-remitting multiple sclerosis (RRMS).
METHODS: A restrospective cohort study analyzed 85 RRMS patients treated with either moderate-efficacy DMTs (interferons, glatiramer acetate, teriflunomide, dimethyl fumarate; n = 48) or high-efficacy DMTs (fingolimod, natalizumab, ocrelizumab, alemtuzumab, cladribine; n = 37). Regular EDSS assessments were used to evaluate relapse severity and subsequent recovery.
RESULTS: Although patients on high-efficacy DMTs tended to experience less severe relapses (ΔEDSS = 0.49 ± 0.59 vs 0.71 ± 0.68 with moderate-efficacy DMTs; p = 0.12), multivariable analysis did not confirm a significant influence of high-efficacy treatment on relapse severity (OR = 0.46; 95 % CI: 0.13-1.61; p = 0.22). Relapse recovery showed a similar gradual improvement in both groups, with a slightly lower increase in disability among patients on high-efficacy DMTs at 6 months (0.26 ± 0.89 vs 0.39 ± 0.73; p = 0.46) and 12 months (0.27 ± 0.83 vs 0.31 ± 0.78; p = 0.98), though without statistically significant differences. Baseline EDSS emerged as the main determinant of relapse severity (OR=0.40; 95 % CI: 0.21-0.77; p = 0.006).
CONCLUSIONS: These findings indicate that, among the DMTs analyzed (both moderate- and high-efficacy), the level of preventive efficacy does not substantially modify relapse severity or recovery once a relapse occurs.